勇闯“无人区”17年，她为何能逆风翻盘？

Core Viewpoint - Shanxi, known for its historical sites and coal resources, is rapidly developing its biopharmaceutical industry, with Jinbo Biotech, founded by Yang Xia, emerging as a key player [1][4]. Company Overview - Yang Xia, after graduating from Shanxi Medical University, identified a gap in the market for human collagen extraction, which was dominated by foreign technology. She founded Jinbo Biotech in 2008 to tackle this challenge [4][6]. - The company successfully developed the world's first recombinant type III humanized collagen product in 2014, breaking the foreign monopoly on this technology [4][6]. Product Innovation - The recombinant type III humanized collagen has a unique 164.88° triple helix structure, enhancing cell adhesion and has applications in advanced implant materials, wound care, and anti-aging cosmetics [6][8]. - Jinbo Biotech's industry standards have been incorporated into the national medical device regulatory system, and it is the only company in China with class III medical device certification for recombinant humanized collagen [6][8]. Technological Advancements - The company is developing an injectable form of recombinant type III humanized collagen gel, which utilizes self-assembling properties to create a honeycomb structure, addressing safety concerns related to residual cross-linking agents [8][10]. - Yang Xia emphasizes that high-end products should be priced based on technology rather than cost, asserting that Jinbo holds pricing power due to its unique technology and extensive R&D investment [8][10]. Market Position and Future Outlook - Jinbo Biotech is positioned as a leader in the emerging recombinant collagen market, gaining recognition as a "star stock" after listing on the Beijing Stock Exchange [6][12]. - Yang Xia acknowledges the volatility of market valuations, stating that a company's performance directly impacts its market value, highlighting the importance of sustained innovation and execution [12].